Genmab A/S
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20

Last updated:

Abstract:

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

Status:
Application
Type:

Utility

Filling date:

7 May 2021

Issue date:

2 Dec 2021